United States

In-depth analysis of Bayer's acquisition of Perfuse Therapeutics for up to $2.45 billion, marking its return to M&A after a 5-year drought. Covers the PER-001 intravitreal implant for glaucoma and diabetic retinopathy, deal structure, endothelin receptor antagonism mechanism, the growing drug-device combination product market, and what it means for ophthalmic medtech manufacturers and investors.

GE HealthCare announced a sweeping restructuring of its business segments and executive leadership team alongside Q1 2026 earnings that missed expectations. Facing $250M in inflationary cost increases driven by memory chips, oil, and freight, the company is raising prices and cutting its profit outlook. Covers the new Advanced Imaging Solutions segment, leadership changes, the inflation impact on medtech supply chains, and what device manufacturers should expect.

Sun Pharmaceutical Industries agreed to acquire Organon & Co. for $11.75 billion in the largest pharmaceutical deal of 2026 and India's largest overseas pharma acquisition. Covers deal structure, Organon's portfolio of women's health products (Nexplanon, NuvaRing) and biosimilars (Hadlima, Renflexis), the drug-device combination products involved, regulatory considerations for combination products, and what the deal means for the women's health and biosimilar device landscape.

In-depth analysis of Danaher's $9.9 billion acquisition of Masimo, the largest medtech deal of 2026. Covers deal structure, strategic rationale, regulatory and antitrust considerations, competitive landscape impact on patient monitoring, and what it means for device manufacturers, hospitals, and investors.

Breaking down the FDA's May 2026 one-day inspection pilot that uses AI (Elsa) to target low-risk facilities. Covers how facilities are selected, what to expect during a screening inspection, how it differs from standard inspections, and what medical device manufacturers must do to stay ready.

The FDA's April 2026 real-time clinical trials initiative uses AI and cloud computing to monitor trial data as it is generated. This guide explains how the program works, the Paradigm Health platform, implications for medical device clinical investigations, and what sponsors must prepare to participate.

How the EPA's 2026 proposed rollback of ethylene oxide emissions standards affects medical device manufacturers, sterilization facilities, and supply chains — the 2024 rule, proposed changes, compliance timelines, and alternative sterilization strategies.

Operational guide to the invalid-result workflow for home-use and self-test IVDs — covering invalid rate targets, lay-user error coding, repeat-test instructions, IFU comprehension, customer support scripts, specimen collection errors, adverse event handling, and postmarket trending.

A comprehensive guide to MDUFA VI — the 2027-2032 FDA medical device user fee agreement covering CDRH staffing restoration, America-First fee restructuring, real-world evidence provisions, fee projections, and practical preparation strategies for device manufacturers.

Practical guide to change control for NGS bioinformatics pipelines in IVD devices — covering variant caller updates, reference database changes, threshold modifications, wet-lab/software interface validation, IEC 62304 documentation, revalidation triggers, and postmarket records.

Operational guide to converting an RUO-labeled assay or reagent into a cleared or approved IVD — covering marketing claims cleanup, distributor scripts, customer notices, historical data triage, validation bridge strategy, complaint transition, sales training, and evidence firewall construction.

How FDA and CDRH staffing cuts are affecting 510(k) review times, pre-submission meetings, and regulatory strategy — with data on CDRH capacity, MDUFA V performance, and practical mitigation strategies for device companies.

Complete guide to the GLP-1 drug-delivery device landscape in 2026 — auto-injector pens, oral delivery devices, combination product regulatory pathways, FDA and EU MDR requirements, and market outlook.

A deep analysis of FDA's January 2025 draft guidance on AI-Enabled Device Software Functions — total product lifecycle approach, data management requirements, bias mitigation strategies, transparency expectations, marketing submission content, and practical steps manufacturers should take before the guidance is finalized.

A comprehensive guide to regulatory sandboxes for medical devices — MHRA AI Airlock (£3.6M expansion), FDA TEMPO pilot for digital health, EU sandbox proposals, and how manufacturers can participate in these programs to accelerate market access.

How Good Clinical Practice applies to medical device clinical trials — navigating ISO 14155:2026 and ICH E6(R3), sponsor and investigator responsibilities, informed consent, safety reporting, and audit readiness.

Protocol-level guide to cleaning validation for reusable surgical instruments — covering artificial soil selection, protein/hemoglobin/TOC endpoints, worst-case device families, manual vs automated cleaning, ANSI/AAMI ST98 acceptance criteria, sample size justification, and report structure.

Dedicated CLIA waiver playbook for IVD manufacturers — covering waived, moderate, and high complexity categories, CW submission content, flex studies, lay-user studies, the Dual 510(k) + CLIA Waiver pathway, review timelines, common deficiencies, and real-world examples.

Practical guide for building a coordinated vulnerability disclosure (CVD) program for medical devices — covering PSIRT setup, vulnerability intake and triage, CVSS scoring, SBOM linkage, field safety notices, FDA Section 524B requirements, EU expectations, and customer communication templates.

Practical guide to using digital twins, synthetic data, and computational modeling in medical device regulatory submissions — covering FDA CM&S credibility guidance, ASME V&V 40, in silico clinical trials, synthetic control arms, model validation pitfalls, and documentation strategies.